EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N -Methyl- d -aspartate Receptor

Michael P D'Erasmo, Nicholas S Akins iD, Peipei Ma, Yao Jing, Sharon A Swanger, Savita K Sharma, Perry W Bartsch, David S Menaldino, Paul J Arcoria, Thi-Thien Bui, Alexandre Pons-Bennaceur, Phuong Le und 15 weitere

ACS Chemical Neuroscience · 2023

DOI: 10.1021/acschemneuro.3c00181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2023. Verfasst von Michael P D'Erasmo und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate, Synaptic Transmission. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subunit-selective inhibition of N-methyl-d-aspartate receptors (NMDARs) is a promising therapeutic strategy for several neurological disorders, including epilepsy, Alzheimer's and Parkinson's disease, depression, and acute brain injury. We previously described the dihydroquinoline-pyrazoline (DQP) analogue 2a (DQP-26) as a potent NMDAR negative allosteric modulator with selectivity for GluN2C/D over GluN2A/B. However, moderate ( 100- and >300-fold selectivity for GluN2C- and GluN2D-containing NMDARs (IC50 0.069 and 0.035 μM, respectively) compared to GluN2A- and GluN2B-containing receptors (IC50 5.2 and 16 μM, respectively) and has no effects on AMPA, kainate, or GluN1/GluN3 receptors. Compound (S)-(-)-2i is 5-fold more potent than (S)-2a. In addition, compound 2i shows a time-dependent enhancement of inhibitory actions at GluN2C- and GluN2D-containing NMDARs in the presence of the agonist glutamate, which could attenuate hypersynchronous activity driven by high-frequency excitatory synaptic transmission. Consistent with this finding, compound 2i significantly reduced the number of epileptic events in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy that is associated with upregulation of the GluN2C subunit. Thus, 2i represents a robust tool for the GluN2C/D target validation. Esterification of the succinate carboxylate improved brain penetration, suggesting a strategy for therapeutic development of this series for NMDAR-associated neurological conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, N-Methyl-D-AspartateSynaptic TransmissionMiceAnimalsStructure-Activity RelationshipGlutamic AcidBrain

Stichwörter der Autor:innen

NR2CNR2Dblood–brain barrierepilepsyseizuretuberous sclerosis complex

Substanzen

Receptors, N-Methyl-D-AspartateGlutamic Acid

Autor:innen und Institutionen

  • Department of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
  • Department of Pharmacology and Chemical Biology, Emory University, Atlanta, Georgia 30322, United States.
  • INMED, INSERM, Aix Marseille University, 13284 Marseille, France.
  • Janssen Research & Development, LLC, San Diego, California 92121, United States.

ORCID-Profile: Nicholas S Akins, Kevin Coe, Dennis C Liotta, Stephen F Traynelis

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NICHD NIH HHS
  • Janssen Research and Development
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Child Health and Human Development
  • National Institute on Aging
  • Brain Research Foundation

Zitieren

APA

D'Erasmo, M. P., Akins, N. S., Ma, P., Jing, Y., Swanger, S. A., Sharma, S. K., Bartsch, P. W., Menaldino, D. S., Arcoria, P. J., Bui, T. T., Pons-Bennaceur, A., Le, P., Allen, J. P., Ullman, E. Z., Nocilla, K. A., Zhang, J., Perszyk, R. E., Kim, S., Acker, T. M., …, & Traynelis, S. F. (2023). Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N -Methyl- d -aspartate Receptor. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.3c00181

Vancouver

D'Erasmo MP, Akins NS, Ma P, Jing Y, Swanger SA, Sharma SK, et al. Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N -Methyl- d -aspartate Receptor. ACS Chemical Neuroscience. 2023. doi:10.1021/acschemneuro.3c00181

BibTeX
@article{DErasmo2023,
  author = {D'Erasmo, Michael P and Akins, Nicholas S and Ma, Peipei and Jing, Yao and Swanger, Sharon A and Sharma, Savita K and Bartsch, Perry W and Menaldino, David S and Arcoria, Paul J and Bui, Thi-Thien and Pons-Bennaceur, Alexandre and Le, Phuong and Allen, James P and Ullman, Elijah Z and Nocilla, Kelsey A and Zhang, Jing and Perszyk, Riley E and Kim, Sukhan and Acker, Timothy M and Taz, Azmain and Burton, Samantha L and Coe, Kevin and Fritzemeier, Russell G and Burnashev, Nail and Yuan, Hongjie and Liotta, Dennis C and Traynelis, Stephen F},
  title = {Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N -Methyl- d -aspartate Receptor},
  journal = {ACS Chemical Neuroscience},
  year = {2023},
  doi = {10.1021/acschemneuro.3c00181}
}
Kostenlos starten →